Skip to search formSkip to main contentSkip to account menu

ganetespib

Known as: 3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methylindol-5-yl)-5-hydroxy-4h-1,2,4-triazole 3h-1,2,4-triazol-3-one, 5-(2,4-dihydroxy-5-(1-methylethyl)phenyl)-2,4-dihydro-4-(1-methyl-1h-indol-5-yl)- 
A synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Ganetespib binds to and inhibits Hsp90… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

STA 9090

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract P4-14-21: A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive…
Introduction: Targeted therapies in HER2+ MBC significantly improve outcomes but efficacy is limited by therapeutic resistance… 
2016
2016
Determining mechanisms of sensitivity and resistance to HSP90 inhibition in non-small cell lung cancer
Some images have been removed from the electronic version of this thesis due to copyright restrictions. The unabridged version… 
2015
2015
A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.
8064 Background: Patients with ALK + non-small cell lung cancer (NSCLC) initially respond to crizotinib, but eventually develop… 
2014
2014
Abstract 1619: Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Most cytotoxic agents are often broadly active… 
2013
2013
GALAXY-1: Randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients.
Background: Ganetespib (G) is a highly potent 2nd-generation Hsp90 inhibitor showing synergistic activity with docetaxel (D) in… 
Review
2013
Review
2013
Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or…
Background: Hsp90 is a molecular chaperone protein required for the stabilization and activation of many proteins, referred to as… 
2013
2013
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer
Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein critical to tumor growth and… 
2012
2012
Preclinical Development Targeting KRAS-Mutant Non – Small Cell Lung Cancer with the Hsp 90 Inhibitor Ganetespib
Mutant KRAS is a feature of more than 25% of non–small cell lung cancers (NSCLC) and represents one of the most prevalent… 
2011
2011
P1-17-08: A Phase II Trial of Ganetespib: Efficacy and Safety in Patients (pts) with Metastatic Breast Cancer (MBC).
Background: Heat shock protein 90 (Hsp90) is a molecular chaperone that maintains the stability of a number of key cellular… 
2011
2011
P3-17-05: Beyond HER2 and Hormonal Agents: The Heat Shock Protein 90 Inhibitor Ganetespib as a Potential New Breast Cancer Therapy.
Background: Ganetespib is a fully synthetic and selective inhibitor of heat shock protein 90 (HSP90), a molecular chaperone…